Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 28, 2015; 21(32): 9598-9606
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9598
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9598
Table 1 Demographic data and liver biopsy results for chronic hepatitis B patients in both entecavir and lamivudine arms at baseline
| ETV | LAM ± ADV | P-value | |
| n | 19 | 23 | |
| Male gender, n (%) | 14 (73.7) | 16 (69.6) | 0.7687 |
| Age (mean ± SD), yr | 43.2 ± 9.8 | 43.7 ± 9.9 | 0.8721 |
| log10 HBV DNA (mean ± SD), IU/mL | 6.6 ± 1.5 | 6.2 ± 1.4 | 0.4019 |
| ALT (mean ± SD), U/L | 107 ± 84 | 96 ± 112 | 0.2450 |
| HBeAg positive, n (%) | 13 (68.42) | 14 (60.87) | 0.6112 |
| Median grade (range) | 11 (0-16) | 9 (3-12) | 0.0749 |
| Median stage (range) | 4 (2-6) | 5 (2-6) | 0.7381 |
| Duration of treatment (mean ± SD), mo | 39 ± 11 | 42 ± 15 | 0.6951 |
-
Citation: Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir
vs lamivudine-based therapy. World J Gastroenterol 2015; 21(32): 9598-9606 - URL: https://www.wjgnet.com/1007-9327/full/v21/i32/9598.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i32.9598